NEW YORK (GenomeWeb) – Pacific Biosciences has received a $10 million payment from Roche for hitting a development milestone that is part of the commercialization and license agreement the companies struck in 2013, according to a PacBio filing with the US Securities and Exchange Commission.

PacBio didn't disclose what development milestone had been met, but noted that it may receive up to $30 million in the future for reaching additional development milestones. It said that the payment will be recorded as contractual revenue in its third quarter financial statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.